Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 8/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.46 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.40 |
| ▸ | GPR6 | P46095 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2392599 | 0.93 | DPP4 (0.50) | DPP4DPP9DPP7DPP8GPR6 | |
| SCHEMBL2391003 | 0.93 | DPP4 (0.50) | DPP4DPP9DPP7DPP8GPR6 | |
| SCHEMBL2391007 | 0.93 | DPP4 (0.50) | DPP4DPP9DPP7DPP8GPR6 | |
| SCHEMBL12289749 | 0.85 | GPR6 (0.38) | DPP4DPP9DPP7DPP8GPR6 | |
| SCHEMBL12292296 | 0.83 | DPP4 (0.39) | DPP4DPP9DPP7DPP8BCL2A1 | |
| SCHEMBL2394852 | 0.81 | ALDH1A1 (0.44) | DPP4DPP9DPP7DPP8BCL2A1 | |
| SCHEMBL2369742 | 0.81 | DPP4 (0.39) | DPP4DPP9DPP7DPP8GPR6 | |
| SCHEMBL2369734 | 0.81 | DPP4 (0.39) | DPP4DPP9DPP7DPP8GPR6 | |
| SCHEMBL2379051 | 0.80 | HTR2C (0.36) | DPP4DPP9DPP7DPP8GPR6 | |
| SCHEMBL2390998 | 0.78 | CDK9 (0.45) | BCL2A1IDO1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539345-B1 | 4-[CYCLOALKYLOXY(HETERO)ARYLAMINO]-THIENO[2,3-D]PYRIMIDINES HAVING MNK1/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2015-07-22 | — | — | EP | disclosed |
| EP-2539345-B1 | 4-[CYCLOALKYLOXY(HETERO)ARYLAMINO]-THIENO[2,3-D]PYRIMIDINES HAVING MNK1/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2015-07-22 | — | — | EP | disclosed |
| US-8754079-B2 | Cycloalkyl containing thienopyrimidines for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| US-8754079-B2 | Cycloalkyl containing thienopyrimidines for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| US-8754079-B2 | Cycloalkyl containing thienopyrimidines for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| US-20110217311-A1 | CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-08 | — | — | US | disclosed |
| US-20110217311-A1 | CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-08 | — | — | US | disclosed |
| US-20110217311-A1 | CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-08 | — | — | US | disclosed |
| WO-2011104334-A1 | 4 - [CYCLOALKYLOXY (HETERO) ARYLAMINO] THIENO [2, 3 - D] PYRIMIDINES HAVING MNKL/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110217311-A1 | CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DTYMK, CMPK1, UCK2 | DPP4 3522/4885DPP9 1342/4885DPP7 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.